Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lomitapide affects HDL composition and function.

Atherosclerosis - 1 Aug 2016

Yahya R, Favari E, Calabresi L, Verhoeven A J M, Zimetti F, Adorni M P, Gomaraschi M, Averna M, Cefalù A B, Bernini F, Sijbrands E J G, Mulder M T, Roeters van Lennep J E

Abstract excerpt

BACKGROUND: Lomitapide reduces low-density lipoprotein-cholesterol (LDL-C) but also high-density lipoprotein-cholesterol (HDL-C) levels. The latter may reduce the clinical efficacy of lomitapide. We investigated the effect of lomitapide on HDL-C levels and on cholesterol efflux capacity (CEC) of HDL in patients with homozygous familial hypercholesterolemia (HoFH). METHODS AND RESULTS: Four HoFH patients were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atherosclerosis
Share to ATP Binding Cassette Transporter 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Cholesterol, HDL

Share to Cholesterol, LDL

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hyperlipoproteinemia Type II

Share to Lipoproteins, HDL

Source

Identifiers

PMID: 27232459
DOI: 10.1016/j.atherosclerosis.2016.05.005

Genes

ABCA1
ABCG1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lomitapide affects HDL composition and function.PMID 27232459Read ↗

Lomitapide for the treatment of hypercholesterolemia.Semantic proximity Read ↗

Lomitapide for the management of homozygous familial hypercholesterolemia.Semantic proximity Read ↗

Treating low HDL--from bench to bedside.Semantic proximity Read ↗

Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.Semantic proximity Read ↗

Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice.Semantic proximity Read ↗

Lomitapide: A Medication Use Evaluation & a Formulary PerspectiveSemantic proximity Read ↗

ABCA8 Regulates Cholesterol Efflux and High-Density Lipoprotein Cholesterol Levels.Semantic proximity Read ↗

MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia.Semantic proximity Read ↗

Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort.Semantic proximity Read ↗

Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia.Semantic proximity Read ↗

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.Semantic proximity Read ↗

Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.